132 related articles for article (PubMed ID: 15243293)
1. (-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: hemodynamic comparison to ZD-6169, WAY-133537, and nifedipine in the anesthetized canine.
Fryer RM; Preusser LC; Calzadilla SV; Hu Y; Xu H; Marsh KC; Cox BF; Lin CT; Gopalakrishnan M; Reinhart GA
J Cardiovasc Pharmacol; 2004 Aug; 44(2):137-47. PubMed ID: 15243293
[TBL] [Abstract][Full Text] [Related]
2. (-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. II. in vivo characterization.
Brune ME; Fey TA; Brioni JD; Sullivan JP; Williams M; Carroll WA; Coghlan MJ; Gopalakrishnan M
J Pharmacol Exp Ther; 2002 Oct; 303(1):387-94. PubMed ID: 12235275
[TBL] [Abstract][Full Text] [Related]
3. (-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. I. In vitro characterization.
Gopalakrishnan M; Buckner SA; Whiteaker KL; Shieh CC; Molinari EJ; Milicic I; Daza AV; Davis-Taber R; Scott VE; Sellers D; Chess-Williams R; Chapple CR; Liu Y; Liu D; Brioni JD; Sullivan JP; Williams M; Carroll WA; Coghlan MJ
J Pharmacol Exp Ther; 2002 Oct; 303(1):379-86. PubMed ID: 12235274
[TBL] [Abstract][Full Text] [Related]
4. K-ATP opener-mediated attenuation of spontaneous bladder contractions in ligature-intact, partial bladder outlet obstructed rats.
Lynch JJ; Brune ME; Lubbers NL; Coghlan MJ; Cox BF; Polakowski JS; King LL; Sullivan JP; Brioni JD
Life Sci; 2003 Mar; 72(17):1931-41. PubMed ID: 12597992
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide K(ATP) channel openers: discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a potent K(ATP) opener that selectively inhibits spontaneous bladder contractions.
Carroll WA; Altenbach RJ; Bai H; Brioni JD; Brune ME; Buckner SA; Cassidy C; Chen Y; Coghlan MJ; Daza AV; Drizin I; Fey TA; Fitzgerald M; Gopalakrishnan M; Gregg RJ; Henry RF; Holladay MW; King LL; Kort ME; Kym PR; Milicic I; Tang R; Turner SC; Whiteaker KL; Yi L; Zhang H; Sullivan JP
J Med Chem; 2004 Jun; 47(12):3163-79. PubMed ID: 15163196
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the potassium channel openers, WAY-133537, ZD6169, and celikalim on isolated bladder tissue and In vivo bladder instability in rat.
Wojdan A; Freeden C; Woods M; Oshiro G; Spinelli W; Colatsky TJ; Sheldon JH; Norton NW; Warga D; Antane MM; Antane SA; Butera JA; Argentieri TM
J Pharmacol Exp Ther; 1999 Jun; 289(3):1410-8. PubMed ID: 10336534
[TBL] [Abstract][Full Text] [Related]
7. In vivo evaluation of the potency and bladder-vascular selectivity of the ATP-sensitive potassium channel openers (-)-cromakalim, ZD6169 and WAY-133537 in rats.
Fabiyi AC; Gopalakrishnan M; Lynch JJ; Brioni JD; Coghlan MJ; Brune ME
BJU Int; 2003 Feb; 91(3):284-90. PubMed ID: 12581020
[TBL] [Abstract][Full Text] [Related]
8. Design and SAR of novel potassium channel openers targeted for urge urinary incontinence. 1. N-Cyanoguanidine bioisosteres possessing in vivo bladder selectivity.
Butera JA; Antane MM; Antane SA; Argentieri TM; Freeden C; Graceffa RF; Hirth BH; Jenkins D; Lennox JR; Matelan E; Norton NW; Quagliato D; Sheldon JH; Spinelli W; Warga D; Wojdan A; Woods M
J Med Chem; 2000 Mar; 43(6):1187-202. PubMed ID: 10737752
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of urinary bladder smooth muscle contractility following partial bladder outlet obstruction in pigs.
Milicic I; Buckner SA; Daza A; Coghlan M; Fey TA; Brune ME; Gopalakrishnan M
Eur J Pharmacol; 2006 Feb; 532(1-2):107-14. PubMed ID: 16487510
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of the novel dihydropyridine potassium channel opener, (9R)-9-(3-iodo-4-methylphenyl)-5,9-dihydro-3H-furo[3,4-b]pyrano[4,3-e]pyridine-1,8(4H,7H)-dione (A-325100), and the regulation of cardiovascular function in conscious and anesthetized beagle dogs.
Fryer RM; Rakestraw PA; Preusser LC; Brune ME; Carroll WA; Buckner SA; Shieh CC; King LL; Marsh KC; Gopalakrishnan M; Cox BF; Reinhart GA
J Cardiovasc Pharmacol; 2005 Aug; 46(2):232-40. PubMed ID: 16044036
[TBL] [Abstract][Full Text] [Related]
11. Low levels of K(ATP) channel activation decrease excitability and contractility of urinary bladder.
Petkov GV; Heppner TJ; Bonev AD; Herrera GM; Nelson MT
Am J Physiol Regul Integr Comp Physiol; 2001 May; 280(5):R1427-33. PubMed ID: 11294764
[TBL] [Abstract][Full Text] [Related]
12. Design and SAR of novel potassium channel openers targeted for urge urinary incontinence. 2. Selective and potent benzylamino cyclobutenediones.
Gilbert AM; Antane MM; Argentieri TM; Butera JA; Francisco GD; Freeden C; Gundersen EG; Graceffa RF; Herbst D; Hirth BH; Lennox JR; McFarlane G; Norton NW; Quagliato D; Sheldon JH; Warga D; Wojdan A; Woods M
J Med Chem; 2000 Mar; 43(6):1203-14. PubMed ID: 10737753
[TBL] [Abstract][Full Text] [Related]
13. ZENECA ZD6169: a novel KATP channel opener with in vivo selectivity for urinary bladder.
Howe BB; Halterman TJ; Yochim CL; Do ML; Pettinger SJ; Stow RB; Ohnmacht CJ; Russell K; Empfield JR; Trainor DA
J Pharmacol Exp Ther; 1995 Aug; 274(2):884-90. PubMed ID: 7636752
[TBL] [Abstract][Full Text] [Related]
14. Zeneca ZD6169 and its analogs from a novel series of anilide tertiary carbinols: in vitro KATP channel opening activity in bladder detrusor.
Li JH; Yasay GD; Zografos P; Kau ST; Ohnmacht CJ; Russell K; Empfield JR; Brown FJ; Trainor DA; Bonev AD
Pharmacology; 1995 Jun; 51(1):33-42. PubMed ID: 7568342
[TBL] [Abstract][Full Text] [Related]
15. Modulation of ATP-sensitive and large-conductance Ca++-activated K+ channels by Zeneca ZD6169 in guinea pig bladder smooth muscle cells.
Hu S; Kim HS
J Pharmacol Exp Ther; 1997 Jan; 280(1):38-45. PubMed ID: 8996179
[TBL] [Abstract][Full Text] [Related]
16. Effects of potassium channel modulators on human detrusor smooth muscle myogenic phasic contractile activity: potential therapeutic targets for overactive bladder.
Darblade B; Behr-Roussel D; Oger S; Hieble JP; Lebret T; Gorny D; Benoit G; Alexandre L; Giuliano F
Urology; 2006 Aug; 68(2):442-8. PubMed ID: 16904481
[TBL] [Abstract][Full Text] [Related]
17. Effect of the ATP-sensitive potassium channel opener ZM226600 on cystometric parameters in rats with ligature-intact, partial urethral obstruction.
Pinna C; Sanvito P; Bolego C; Cignarella A; Puglisi L
Eur J Pharmacol; 2005 May; 516(1):71-7. PubMed ID: 15913601
[TBL] [Abstract][Full Text] [Related]
18. Zeneca ZD6169 activates ATP-sensitive K+ channels in the urinary bladder of the guinea pig.
Heppner TJ; Bonev A; Li JH; Kau ST; Nelson MT
Pharmacology; 1996 Sep; 53(3):170-9. PubMed ID: 8931102
[TBL] [Abstract][Full Text] [Related]
19. Effects of ATP-sensitive K+ channel openers and tolterodine on involuntary bladder contractions in a pig model of partial bladder outlet obstruction.
Fey TA; Gopalakrishnan M; Strake JG; King LL; Brioni JD; Sullivan JP; Coghlan MJ; Brune ME
Neurourol Urodyn; 2003; 22(2):147-55. PubMed ID: 12579633
[TBL] [Abstract][Full Text] [Related]
20. Effects of ZD6169, a K(ATP) channel opener, on the micturition reflex in the rat.
Yu Y; de Groat WC
J Pharmacol Exp Ther; 1999 Aug; 290(2):825-31. PubMed ID: 10411598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
